Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries.

[1]  G. Bedoya,et al.  Native American ancestry significantly contributes to neuromyelitis optica susceptibility in the admixed Mexican population , 2020, Scientific Reports.

[2]  Jacqueline Palace,et al.  Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  L. Vécsei,et al.  A population‐based epidemiological study of neuromyelitis optica spectrum disorder in Hungary , 2019, European journal of neurology.

[4]  Ramil Hakim,et al.  Epidemiology of NMOSD in Sweden from 1987 to 2013 , 2019, Neurology.

[5]  A. Damasceno,et al.  Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD). , 2019, Multiple sclerosis and related disorders.

[6]  J. Frederiksen,et al.  Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark , 2018, Neurology.

[7]  G. Cutter,et al.  Mortality in neuromyelitis optica is strongly associated with African ancestry , 2018, Neurology: Neuroimmunology & Neuroinflammation.

[8]  Robert E Handsaker,et al.  A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica , 2018, Nature Communications.

[9]  F. Paul,et al.  Worldwide prevalence of neuromyelitis optica spectrum disorders , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[10]  K. Fujihara,et al.  Nationwide epidemiological study of neuromyelitis optica in Japan , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  F. Paul,et al.  Ethnic Differences in Clinical Manifestation of Neuromyelitis Optica Spectrum Disorder , 2018 .

[12]  M. Leite,et al.  Prevalence of neuromyelitis optica spectrum disorder in the multi-ethnic Penang Island, Malaysia, and a review of worldwide prevalence. , 2018, Multiple sclerosis and related disorders.

[13]  X. Montalban,et al.  Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates , 2018, Multiple sclerosis.

[14]  T. Solomon,et al.  What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients , 2017, Journal of Neurology.

[15]  K. Dear,et al.  Incidence and prevalence of NMOSD in Australia and New Zealand , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  F. Paul,et al.  Influence of female sex and fertile age on neuromyelitis optica spectrum disorders , 2016, Multiple sclerosis.

[17]  Jacqueline Palace,et al.  Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  Thomas Mailund,et al.  Nationwide Genomic Study in Denmark Reveals Remarkable Population Homogeneity , 2016, Genetics.

[19]  P. Trillenberg,et al.  Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  T. Ben-Hur,et al.  Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel , 2016, Journal of Neuroimmunology.

[21]  J. Sauver,et al.  Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum , 2016, Annals of neurology.

[22]  R. Hintzen,et al.  Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: About one in a million , 2016, Multiple sclerosis journal - experimental, translational and clinical.

[23]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[24]  F. Paul,et al.  MRI characteristics of neuromyelitis optica spectrum disorder , 2015, Neurology.

[25]  B. Weinshenker,et al.  Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. , 2015, JAMA neurology.

[26]  Jacqueline Palace,et al.  Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes , 2015, Journal of Neurology.

[27]  Jacqueline Palace,et al.  Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset , 2014, Multiple sclerosis.

[28]  D. Falush,et al.  A Genetic Atlas of Human Admixture History , 2014, Science.

[29]  A. Lutterotti,et al.  Neuromyelitis Optica in Austria in 2011: To Bridge the Gap between Neuroepidemiological Research and Practice in a Study Population of 8.4 Million People , 2013, PloS one.

[30]  M. Boggild,et al.  The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom , 2013, Journal of Neurology.

[31]  K. Fujihara,et al.  Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. , 2012, Brain : a journal of neurology.

[32]  Yuge Wang,et al.  HLA-DPB1*0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in Southern Han Chinese , 2011, Journal of Neuroimmunology.

[33]  A. Bíró,et al.  A Y-chromosomal comparison of the Madjars (Kazakhstan) and the Magyars (Hungary). , 2009, American journal of physical anthropology.

[34]  P. Vermersch,et al.  Is neuromyelitis optica associated with human leukocyte antigen? , 2009, Multiple sclerosis.

[35]  B. Weinshenker,et al.  A secondary progressive clinical course is uncommon in neuromyelitis optica , 2007, Neurology.

[36]  B. Weinshenker,et al.  Revised diagnostic criteria for neuromyelitis optica , 2006, Neurology.